Santarus 8-K 2005
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Item 7.01 Regulation FD Disclosure.
Santarus, Inc. discloses that the 45-day period following receipt of notice of acceptance by the U.S. Food and Drug Administration of Santarus’ new drug application for Zegerid® Chewable Tablets has expired and that Santarus did not receive notice of a patent infringement suit from AstraZeneca plc and related patent holders concerning Zegerid Chewable Tablets.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.